TACSTD2 and endometrial serous adenocarcinoma: Though Trop-2 has been shown to be an excellent candidate antigen for targeted immunotherapy in multiple gynecologic malignancies including EEC [24], uterine papillary serous carcinomas [22], chemotherapy-resistant [23] and sensitive ovarian carcinomas [32], and cervical carcinomas [25], this is the first proof that Trop-2 overexpression can also prognosticate patient outcome in EEC.